Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic can
--(BUSINESS WIRE)-- Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. Additional muscle- and blood-related programs are in earlier-stage development. For more information, please visit www.axcellahealth.com.
| Company: | Axcella Health Inc. | ||
|
|
| ||
| Headquarters Address: | 840 Memorial Dr., Third Floor | ||
|
| CAMBRIDGE, MA 02139 | ||
|
|
| ||
| Main Telephone: | 857-320-2200 | ||
|
|
| ||
| Website: | |||
|
|
| ||
| Ticker: | AXLA(NASDAQ) | ||
|
|
| ||
| Type of Organization: | Public | ||
|
|
| ||
| Industry: | Biotechnology | ||
|
|
| ||
| Key Executives: | CEO: Bill Hinshaw | ||
|
|
| ||
| Investor Relations |
| ||
| Contact: | Jason Fredette | ||
| Phone: | 7814240946 | ||
| Email: |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005860/en/
Source: Axcella Health Inc.
View this news release online at:
http://www.businesswire.com/news/home/20200924005860/en